KIMS Announces Q1 FY26 Results: Revenue ₹879 Cr, EBITDA ₹200 Cr
The results indicate continued growth but with some margin compression, and the expansion plans suggest future growth potential. This combination results in a medium impact.
The announcement presents a mix of positive revenue growth and some decline in profitability metrics (EBITDA margin and PAT), resulting in a neutral sentiment.
* KIMS reports consolidated Q1 FY26 results with total revenue of ₹879 crore, a 26.8% YoY growth and 9.6% QoQ growth. * EBITDA stood at ₹200 crore, reflecting an 8.5% YoY increase but a 1.4% QoQ decrease. * EBITDA margin was 22.7% compared to 26.6% in Q1 FY25 and 25.3% in Q4 FY25. * PAT for Q1 FY26 was ₹85 crore, against ₹95 crore and ₹106 crore in Q1 FY25 and Q4 FY25 respectively. * Consolidated EPS for Q1 FY26 was ₹1.96, a 9.2% YoY decrease. * IP Volumes grew by 15.3% YoY to 57,275, and OP Volumes increased by 19.3% YoY to 5,02,492. * ARPOB increased by 11.8% YoY to ₹43,011, and ARPP grew by 9.8% YoY to ₹1,53,094. * Expansion plans include new facilities in Bangalore, Ongole, Anantapur, Kondapur and Rajahmundry.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.